The future of warfarin pharmacogenetics in under-represented minority groups

Larisa H. Cavallari*, Minoli A. Perera

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

46 Scopus citations

Abstract

Genotype-based dosing recommendations are provided in the US FDA-approved warfarin labeling. However, data that informed these recommendations were from predominately Caucasian populations. Studies show that variants contributing to warfarin dose requirements in Caucasians provide similar contributions to dose requirements in US Hispanics, but significantly lesser contributions in African-Americans. Further data demonstrate that variants occurring commonly in individuals of African ancestry, but rarely in other racial groups, significantly influence dose requirements in African-Americans. These data suggest that it is important to consider variants specific for African-Americans when implementing genotype-guided warfarin dosing in this population.

Original languageEnglish (US)
Pages (from-to)563-576
Number of pages14
JournalFuture Cardiology
Volume8
Issue number4
DOIs
StatePublished - Jul 2012

Keywords

  • African-American
  • CYP2C9
  • Hispanic
  • VKORC1
  • polymorphism
  • warfarin

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'The future of warfarin pharmacogenetics in under-represented minority groups'. Together they form a unique fingerprint.

Cite this